The Role of Toll-Like Receptors (TLRs) in Infection and Inflammation: Third Edition
A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Immunology".
Deadline for manuscript submissions: 31 January 2025 | Viewed by 34
Special Issue Editors
Interests: toll-like receptors; NF-kappaB; COVID-19; cytokines; gene therapy; immune therapy
Special Issues, Collections and Topics in MDPI journals
Interests: immunology of viral infections; host cell targeted antivirals; virus cell interaction
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Toll-like receptors (TLRs) represent a powerful system for the recognition and elimination of pathogen-associated molecular patterns (PAMPs) from bacteria, viruses, and other pathogens and of damage-associated molecular patterns (DAMPs) released from dying or lytic cells. TLRs are mainly expressed on immune cells but can also be present on some tissue-resident cell populations. Typical PAMPs are cell wall components of bacterial and viral pathogens, conserved proteins, or pathogenic nucleic acids, including viral RNA and DNA.
Activation of TLRs leads to the production of proinflammatory cytokines and type I interferons, which are important for induction of the host immune response against bacterial, fungal, and viral infections and malaria. However, dysregulation and overstimulation can be detrimental, leading to hyperinflammation, sepsis, and loss of tissue integrity. TLRs are involved in the pathogenesis of acute viral infections, including in the case of COVID-19. Altogether, activation of TLR plays a deciding role in both the induction of immunity and the pathophysiological effects associated with excessive activation, indicating TLRs are promising targets for pharmacological intervention and treatment.
Topics of interest include but are not limited to:
- Activation of TLR and their downstream signaling pathways and their correlation with the immunology and pathophysiology of bacterial and viral infectious diseases.
- Translational research, pharmacological and medical interventions with TLR activation and signaling, and their use as therapeutic targets for bacterial and viral infectious diseases, including COVID-19.
- Clinical or model studies, though only in conjunction with biomolecular experiments.
Dr. Ralf Kircheis
Prof. Dr. Oliver Planz
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- toll-like receptors (TLR)
- pathogen associated molecular patterns (PAMPs)
- sepsis
- bacterial infections
- viral infections
- Myd88
- TRIF
- NF-kappaB
- COVID-19
- coagulopathies
